Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash & Current Investments (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Cash & Current Investments for 6 consecutive years, with $77.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Current Investments rose 2283.81% to $77.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $77.3 million, a 2283.81% increase, with the full-year FY2024 number at $97.5 million, up 636.06% from a year prior.
  • Cash & Current Investments was $77.3 million for Q3 2025 at Inhibikase Therapeutics, down from $87.7 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $97.5 million in Q4 2024 to a low of $3.2 million in Q3 2024.
  • A 5-year average of $37.6 million and a median of $26.5 million in 2022 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: surged 601525.64% in 2021, then crashed 80.73% in 2024.
  • Inhibikase Therapeutics' Cash & Current Investments stood at $40.8 million in 2021, then plummeted by 43.44% to $23.1 million in 2022, then plummeted by 42.51% to $13.3 million in 2023, then skyrocketed by 636.06% to $97.5 million in 2024, then decreased by 20.73% to $77.3 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Cash & Current Investments are $77.3 million (Q3 2025), $87.7 million (Q2 2025), and $93.2 million (Q1 2025).